Website profile

@Twitter

BIOENGINEER.ORG - Bioengineering

  • 3,419articles · 30d
  • 53+ min agolatest article
  • Aug 14, 2026earliest in window
  • 98%with images
  • 76avg words
articles per day
Categories
  • Science & Nature 2,015
  • Science & Technology 1,872
  • Health & Wellness 1,683
  • Medical 1,317
  • Health 1,139
  • STEM 895
  • Environment 305
  • Food & Drink 230

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BIOENGINEER.ORG
bioengineer.org > commentary-challenges-claims-of-exceptional-melflufen-responses-in-multiple-myeloma

Commentary Challenges Claims of Exceptional Melflufen Responses in Multiple

1+ hour, 6+ min ago   (746+ words) A new commentary published in the Journal of Cancer Research and Clinical Oncology is challenging how exceptional individual responses to an experimental multiple myeloma drug should be interpreted, warning that remarkable case reports can inadvertently obscure evidence that a treatment…...

BIOENGINEER.ORG
bioengineer.org > sleep-exercise-and-support-may-shield-cancer-caregivers-from-mental-distress

Sleep, Exercise, and Support May Shield Cancer Caregivers From Mental

1+ hour, 10+ min ago   (809+ words) Caring for a loved one through cancer is one of the most emotionally demanding roles in modern medicine, and a new nationwide analysis confirms just how heavy that burden can be....

BIOENGINEER.ORG
bioengineer.org > bispecific-antibody-meets-antibody-drug-conjugate-in-promising-small-cell-lung-cancer-trial

Bispecific Antibody Meets Antibody-Drug Conjugate in Promising Small Cell

1+ hour, 21+ min ago   (770+ words) Small cell lung cancer has long been one of the most difficult malignancies to treat, marked by aggressive growth, early dissemination and a stubborn tendency to develop resistance to standard therapies....

BIOENGINEER.ORG
bioengineer.org > dual-immunotherapy-edges-out-pembrolizumab-in-cost-effectiveness-for-msi-high-colorectal-cancer

Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for

1+ hour, 22+ min ago   (649+ words) A new health economic analysis has found that the combination of nivolumab plus ipilimumab, a dual immune checkpoint inhibitor regimen, may deliver more quality-adjusted life years at lower total cost than pembrolizumab, the currently recommended first-line immunotherapy, for patients with…...

BIOENGINEER.ORG
bioengineer.org > lab-models-take-center-stage-in-the-race-to-improve-cancer-immunotherapy

Lab Models Take Center Stage in the Race to Improve Cancer Immunotherapy

1+ hour, 46+ min ago   (583+ words) Cancer immunotherapy has transformed the treatment landscape for many patients with solid tumors, delivering durable responses in diseases that once resisted nearly every therapeutic approach....

BIOENGINEER.ORG
bioengineer.org > cholangioscopy-shows-strong-accuracy-for-detecting-bile-duct-cancer

Cholangioscopy Shows Strong Accuracy for Detecting Bile Duct Cancer

2+ hour, 13+ min ago   (621+ words) For patients facing the terrifying possibility of bile duct cancer, the diagnostic journey is often exhausting and inconclusive. Scans can reveal a blockage, but they cannot tell doctors whether it is caused by a tumor, scarring, or inflammation....

BIOENGINEER.ORG
bioengineer.org > immune-side-effects-may-signal-stronger-tumor-shrinkage-and-longer-survival-in-gastric-cancer

Immune Side Effects May Signal Stronger Tumor Shrinkage and Longer Survival

3+ hour, 3+ min ago   (628+ words) When patients with advanced gastric cancer receive immune checkpoint inhibitors, one of the most puzzling phenomena in modern oncology is the apparent paradox that side effects can be good news....

BIOENGINEER.ORG
bioengineer.org > dual-pi3k-mtor-inhibitor-vdc597-shows-promise-against-canine-lymphoma-and-leukemia-in-lab-studies

Dual PI3K/mTOR Inhibitor VDC597 Shows Promise Against Canine Lymphoma and

3+ hour, 45+ min ago   (732+ words) Lymphoma is one of the most common diagnoses in veterinary oncology, accounting for roughly 7 to 24 percent of all canine cancers and fully 80 percent of hematopoietic tumors in dogs....

BIOENGINEER.ORG
bioengineer.org > expressive-writing-helps-rural-breast-cancer-survivors-find-strength-after-cancer

Expressive Writing Helps Rural Breast Cancer Survivors Find Strength After

3+ hour, 45+ min ago   (75+ words) For women living far from hospitals and support groups, a cancer diagnosis can feel like an isolation sentence stacked on top of a medical one. New research suggests that something as simple as writing about their deepest thoughts and feelings…...

BIOENGINEER.ORG
bioengineer.org > protacs-move-from-lab-concept-to-clinical-reality-in-targeted-protein-degradation

PROTACs Move From Lab Concept to Clinical Reality in Targeted Protein

4+ hour ago   (746+ words) A sweeping new review published in Discover Chemistry charts the remarkable rise of proteolysis-targeting chimeras, better known as PROTACs, from a bold theoretical idea to one of the most closely watched platforms in modern drug discovery. Written by Sandip G....